Dr Reddy's gets DCGI go-ahead to conduct Phase 2/3 human trials of Sputnik V in India

Credit: IndiaTimes- Published on October 17, 2020
After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian Covid-19 vaccine Sputnik V, the company and Russia’s sovereign wealth fund Russian Direct Investment Fund (RDIF) have now received the Drug Control General of India...

Video credit: HT Digital Content
Published on October 17, 2020 -  05:47
Covid-19 cases dip, PM Modi calls for ‘speedy delivery’ of vaccines
As coronavirus infections continue to dip for the third consecutive week, Prime Minister Narendra Modi on Saturday called for a speedy delivery of Covid-19 vaccine once they are developed. Charing a high-level meet, the PM called for using the election infrastructure of the country for the speedy delivery of the vaccines. His remarks come on day the country’s drug controller allowed clinical trials of Russia’s Sputnik V vaccine candidate and the Serum Institute of India, which is to manufacture the Oxford vaccine candidate, said that India may get a Covid-19 vaccine by March next year. Top stories in this editorji evening playlist.

You are here


💡 newsR Knowledge: Other News Mentions


Gam-COVID-Vac

Viral vector vaccine candidate based on human adenovirus
According to the company, the Sputnik V vaccine is 95% effective and will cost less than USD 10 or Rs 740 internationally.
Credit: DNA - Published 2 days ago

Russia’s Sputnik V Covid-19 vaccine, that reported an efficacy of over 95%, will be twice as cheap as those by Pfizer and Moderna with similar positive..
Credit: IndiaTimes - Published 2 days ago



Russian Direct Investment Fund

Fund established by the Russian government in June 2011

Related videos from verified sources

Cyclone Nivar is gradually intensifying, could cause damage to crops: IMD DGM 01:46
Credit: ANI - Published 2 days ago 


India has invested heavily in peace, development of Afghanistan: S Jaishankar 01:18
Credit: ANI - Published 2 days ago 


'Covaxin phase-3 trial probably largest clinical trial in India': Principal Investigator 01:36
Credit: ANI - Published 5 days ago 


Related news from verified sources

After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian...
on October 17, 2020 • IndiaTimes

The Drug Controller General of India (DCGI) has granted approval to Dr Reddy's, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3...
on October 17, 2020 • Mid-Day

After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian...
on October 17, 2020 • IndiaTimes

You might like